Cognition Therapeutics Q1 2026 Net Loss Narrowed to $4.6M, FDA Meeting Set for May 20

COGNITION THERAPEUTICS INC

2026-Q1 EPS reported -$0.05

Net loss for Q1 2026 was $4.6M ($0.05/share), down from $8.5M ($0.14/share) in Q1 2025.
Cash, cash equivalents, and restricted cash were $31.2M as of March 31, 2026; NIA grant funds $25.6M.
FDA Division of Psychiatry meeting scheduled for May 20, 2026 to discuss registrational plans for zervimesine in DLB psychosis.
Topline results from Phase 2 START study (COG0203) in early Alzheimer's expected in 2027.
Presented two posters at AD/PD 2026 conference on zervimesine's effect and composite endpoint for DLB.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

COGNITION THERAPEUTICS INC reported the first quarter ended March 31, 2026 results: net income $4.6 million, EPS $(0.05) per basic and diluted share.

Period: the first quarter ended March 31, 2026
Net income: $4.6 million
EPS: $(0.05) per basic and diluted share
Result: reported results

Exact text from the filing

expenses was driven primarily by lower stock compensation, compensation and professional fees. Cognition Therapeutics, Inc. www.cogrx.com The Company reported a net loss of $4.6 million, or $(0.05) per basic and diluted share for the first quarter ended March 31, 2026, compared to a net loss of $8.5 million, or $(0.14) per basic and diluted share for the same

View on SEC.gov

Browse all earnings releases →

COGNITION THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001104659-26-057186

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.